10 Small-Cap Stocks With Huge Growth Potential
On February 19, Ben Snider, Goldman Sachs chief U.S. equity strategist, appeared on CNBC’s ‘Money Movers’ to talk about his playbook for equities, among other things.
Nuvation Bio Inc. (NUVB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 25,954,439 | $232,551,773 | 31.28% | |
| 2. | Laurion Capital Management Benjamin A. Smith | 7,852,638 | $70,359,636 | -20% | 2.62% |
| 3. | Tang Capital Management Kevin C. Tang | 3,857,457 | $34,562,815 | -9% | 1.71% |
| 4. | Abrams Capital Management David Abrams | 3,811,513 | $34,151,156 | 0.6% | |
| 5. | Redmile Group Jeremy Green | 3,163,256 | $28,342,774 | +5% | 2.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.71 | 10,000 | $17,100.00 | 29,591 | 2025-06-18 | Filing | |
| $1.79 | 4,000 | $7,160.00 | 9,902 | 2025-06-17 | Filing | |
| $1.84 | 3,300 | $6,055.50 | 5,902 | 2025-06-16 | Filing | |
| $1.81 | 50,000 | $90,350.00 | 81,000 | 2025-06-16 | Filing | |
| $1.80 | 24,000 | $43,200.00 | 50,000 | 2025-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 150,000 | $1,173,255.00 | 18,000 | 2025-12-01 | Filing | |
| $8.00 | 10,000 | $80,000.00 | 18,000 | 2025-11-26 | Filing | |
| $7.50 | 10,000 | $75,000.00 | 18,000 | 2025-11-25 | Filing | |
| $7.23 | 300,000 | $2,168,100.00 | 0 | 2025-11-20 | Filing | |
| $7.23 | 69,051 | $499,031.58 | 0 | 2025-11-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 51,424,981 | $460,767,830 | 0.02% | |
| 2. | 24,669,776 | $221,041,196 | 0% | |
| 3. | 15,555,606 | $139,378,229 | 0% | |
| 4. | 8,081,089 | $72,406,557 | 25.27% | |
| 5. | 5,858,782 | $52,494,687 | 0% |
News See All
Truist Highlights Nuvation Bio's (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors
Nuvation Bio Inc. (NYSE:NUVB) is one of the best high short interest stocks with biggest upside potential.
10 Best Small-Cap Stocks Ready to Explode in 2026
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations
TheFly reported on January 12 that H.C. Wainwright reduced its price target on NUVB to $17 from $18 while maintaining a Buy rating.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
10 Stocks Under $10 with High Potential
On January 17, Ryan Detrick from Carson Group appeared on a CNBC Television interview to discuss the current market situation and future outlook.
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib
Nuvation Bio Inc. (NYSE:NUVB) is among the 14 best booming stocks to buy right now.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result
“The results published in the journal of Neuro-Oncology demonstrate Safusidenib’s impressive response rate and prolonged progression-free survival that suggest the possibility to delay chemoradiation...